MediQuest Therapeutics, Inc. Completes Phase IIIA Clinical Trials for Raynaud's Phenomenon

(Bothell, WA - 8 December 2005) MediQuest Therapeutics, Inc. recently concluded its Phase IIIA clinical study on Raynaud's phenomenon conducted at two of the leading medical centers in the United States.

The study, comprising 36 patients, aimed to determine, in comparison to a placebo control, the response to two dosage strengths of a topical proprietary organogel formulation of nitroglycerin, MQX-503. Blood flow and skin temperature were measured in the fingers of patients with moderate to severe Raynaud's phenomenon, following lab-controlled exposure to cold temperatures. Blood flow was determined by scanning laser Doppler equipment and skin temperature was measured using attached thermistor probes.

Raynaud's phenomenon is a condition caused by moderate to severe constriction of blood vessels in the hands and feet, usually triggered during colder weather. The condition is either of a primary nature or is secondary to scleroderma and other such autoimmune diseases. More than six million people in the United States suffer from Raynaud's. Many of these patients are women who also experience pain caused by the chronic vasospasm episodes in their hands and feet.

Preliminary results from clinic tests of MQX-503 demonstrated enhanced blood flow within five minutes of application to the fingers. A Phase IIIB "in life" study on 200 patients is currently enrolling at various sites across the United States and Canada during the current winter season.